Trial
NCT05442684
A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine
Phase IIIWITHDRAWNREGULATORYConfidence: HIGH
Sponsor
CanSino Biologics Inc.
Collaborators
—
Condition
COVID-19
Intervention
Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
Why stopped
The trial protocol was not approved by the regulatory authorities.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-18